We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+6.07%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$4.02M
AUM Growth
-$255K
Cap. Flow
-$384K
Cap. Flow %
-9.53%
Top 10 Hldgs %
100%
Holding
12
New
1
Increased
2
Reduced
–
Closed
5

Top Buys

1
GLD icon
SPDR Gold Trust
GLD
+$295K
2
ALXO icon
ALX Oncology
ALXO
+$39.9K
3
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$8.35K

Top Sells

1
SYRE icon
Spyre Therapeutics
SYRE
+$292K
2
DFTX
Definium Therapeutics
DFTX
+$210K
3
CMPX icon
Compass Therapeutics
CMPX
+$158K
4
SABS icon
SAB Biotherapeutics
SABS
+$39.4K
5
CNTX icon
Context Therapeutics
CNTX
+$27.1K

Sector Composition

1 Healthcare 9.84%
2 Financials 8.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GLD icon
1
SPDR Gold Trust
GLD
$130B
$3.28M 81.5%
7,623
+659
+9% +$295K
BRK.B icon
2
Berkshire Hathaway Class B
BRK.B
$1.06T
$348K 8.66%
727
+17
+2% +$8.35K
KYTX icon
3
Kyverna Therapeutics
KYTX
$453M
$162K 4.03%
18,773
– –
LXEO icon
4
Lexeo Therapeutics
LXEO
$368M
$80K 1.99%
13,943
– –
XFOR icon
5
X4 Pharmaceuticals
XFOR
$360M
$64.2K 1.6%
15,557
– –
IKT icon
6
Inhibikase Therapeutics
IKT
$331M
$47.8K 1.19%
28,453
– –
ALXO icon
7
ALX Oncology
ALXO
$283M
$42K 1.04%
+20,946
New +$39.9K
CMPX icon
8
Compass Therapeutics
CMPX
$369M
– –
-29,495
Closed -$158K
CNTX icon
9
Context Therapeutics
CNTX
$55.1M
– –
-18,403
Closed -$27.1K
DFTX
10
Definium Therapeutics
DFTX
$5.88B
– –
-15,688
Closed -$210K
SABS icon
11
SAB Biotherapeutics
SABS
$271M
– –
-10,527
Closed -$39.4K
SYRE icon
12
Spyre Therapeutics
SYRE
$8.7B
– –
-8,919
Closed -$292K

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q1 2026 Portfolio in Review

As of Q1 2026, Caxton Corporation held 12 positions worth $4.02M, down 6% from $4.28M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Caxton Corporation withdrew a net $384K in Q1 2026, closing 5 positions. Its most notable exit was Spyre Therapeutics, an estimated $292K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.8% of assets, down from 27% a quarter earlier, followed by Financials.

Against the trend, Caxton Corporation opened a new position in ALX Oncology worth $42K.

  • Caxton Corporation's largest Q1 2026 buy was ALX Oncology: 20,946 shares worth $42K.
  • Caxton Corporation added most to SPDR Gold Trust in Q1 2026, an estimated $295K increase.
  • Caxton Corporation fully exited Spyre Therapeutics in Q1 2026, selling an estimated $292K.
  • Caxton Corporation's ten largest holdings make up 100% of its $4.02M portfolio in Q1 2026.
  • Caxton Corporation opened 1 new position and closed 5 in Q1 2026.
  • Caxton Corporation's portfolio value fell 6% quarter-over-quarter to $4.02M.

Based on Caxton Corporation's 13F filing for Q1 2026, filed 14 May 2026.